Morgan et al. reported that phosphorylation of Tyr1173 of EGFR is the target of erlotinib [30],while we observed that phosphorylation of Tyr845 and Tyr1068 of EGFR could be regulated by CHIP,thus the multitarget treatment may explain the phenomena that CHIP enhanced the efficacy of erlotinib on pancreatic tumor growth and apoptosis. Here, STUB1 is linked to pancreatic neoplasm.